A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus

Annals of the Rheumatic Diseases

Volumn 69, Issue 5, 2010, Pages 834-840

  Svenungsson, Elisabet ^a   Gustafsson, Johanna ^a   Leonard, Dag ^b   Sandling, Johanna ^b   Gunnarsson, Iva ^a   Nordmark, Gunnel ^b   Jönsen, Andreas ^c   Bengtsson, Anders A ^c   Sturfelt, Gunnar ^c   Rantapää Dahlqvist, Solbritt ^d   Elvin, Kerstin ^a   Sundin, Ulf ^a   Garnier, Sophie ^b   Simard, Julia F ^e   Sigurdsson, Snaevar ^b   Padyukov, Leonid ^a   Syvänen, Ann Christine ^b   Rönnblom, Lars ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN ANTIBODY; PHOSPHOLIPID ANTIBODY; PROTHROMBIN ANTIBODY; STAT4 PROTEIN;

ADULT; ALLELE; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNICITY; FEMALE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; ALLELES; ANTIBODIES, ANTIPHOSPHOLIPID; BRAIN ISCHEMIA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; STAT4 TRANSCRIPTION FACTOR;

EID: 77951563846     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.115535     Document Type: Article

References (47)

1. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54:2550-2557
2. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-415 (Pubitemid 27084212)
3. Björnådal L, Yin L, Granath F, et al. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-1995. J Rheumatol 2004;31:713-719
4. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-2337 (Pubitemid 32977500)
5. Svenungsson E, Jensen-Urstad K, Heimbürger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001;104:1887-1893 (Pubitemid 32983229)
6. Toloza SM, Uribe AG, McGwin G Jr, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004;50:3947-3957 (Pubitemid 39643943)
7. Westerweel PE, Luyten RK, Koomans HA, et al. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 2007;56:1384-1396 (Pubitemid 46764065)
8. Calvo-Alén J, Alarcón GS, Tew MB, et al.; LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort: XXXIV. Deficient mannose-binding lectin exon 1 polymorphisms are associated with cerebrovascular but not with other arterial thrombotic events. Arthritis Rheum 2006;54:1940-1945 (Pubitemid 43877943)
9. Øhlenschlaeger T, Garred P, Madsen HO, et al. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med 2004;351:260-267
10. Szalai AJ, Alarcón GS, Calvo-Alén J, et al. Systemic lupus erythematosus in a multiethnic US Cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events. Rheumatology (Oxford) 2005;44:864-868 (Pubitemid 41511179)
11. Harley JB, Alarcón-Riquelme ME, Criswell LA, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008;40:204-210
12. Hom G, Graham RR, Modrek B, et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008;358:900-909 (Pubitemid 351397089)
13. Abelson AK, Delgado-Vega AM, Kozyrev SV, et al. STAT4 Associates with SLE through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. Ann Rheum Dis 2009;68:1746-1753
14. Kobayashi S, Ikari K, Kaneko H, et al. Association of STAT4 with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in the Japanese population. Arthritis Rheum 2008;58:1940-1946 (Pubitemid 351988085)
15. Palomino-Morales RJ, Rojas-Villarraga A, González CI, et al. STAT4 but not TRAF1/C5 variants influence the risk of developing rheumatoid arthritis and systemic lupus erythematosus in Colombians. Genes Immun 2008;9:379-382 (Pubitemid 351791494)
16. Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007;357:977-986 (Pubitemid 47367077)
17. Sigurdsson S, Nordmark G, Garnier S, et al. A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum Mol Genet 2008;17:2868-2876
18. Kaplan MH. STAT4: a critical regulator of inflammation in vivo. Immunol Res 2005;31:231-242
19. Rönnblom L, Eloranta ML, Alm GV. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 2006;54:408-420 (Pubitemid 43228615)
20. Denny MF, Thacker S, Mehta H, et al. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 2007;110:2907-2915 (Pubitemid 350006944)
21. Taylor KE, Remmers EF, Lee AT, et al. Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet 2008;4:e1000084.
22. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-1277
23. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-369 (Pubitemid 26085211)
24. Fan JB, Oliphant A, Shen R, et al. Highly parallel SNP genotyping. Cold Spring Harb Symp Quant Biol 2003;68:69-78.
25. Bell PA, Chaturvedi S, Gelfand CA, et al. SNPstream UHT: ultra-high throughput SNP genotyping for pharmacogenomics and drug discovery. Biotechniques 2002;74(Suppl 70-72);76-77. (Pubitemid 34615027)
26. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
27. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000;15:145-151
28. Goel N, Ortel TL, Bali D, et al. Familial antiphospholipid antibody syndrome: criteria for disease and evidence for autosomal dominant inheritance. Arthritis Rheum 1999;42:318-327 (Pubitemid 29072850)
29. Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827-1832 (Pubitemid 36237580)
30. Horita T, Atsumi T, Yoshida N, et al. STAT4 single nucleotide polymorphism, rs7574865 G/T, as a risk for antiphospholipid syndrome. Ann Rheum Dis 2009;68:1366-1367
31. Yin H, Borghi MO, Delgado-Vega AM, et al. Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome. Arthritis Rheum 2009;60:2468-2471
32. Jacob CO, Zang S, Li L, et al. Pivotal role of Stat4 and Stat6 in the pathogenesis of the lupus-like disease in the New Zealand mixed 2328 mice. J Immunol 2003;171:1564-1571 (Pubitemid 36900092)
33. Xu Z, Duan B, Croker BP, et al. STAT4 deficiency reduces autoantibody production and glomerulonephritis in a mouse model of lupus. Clin Immunol 2006;120:189-198 (Pubitemid 44080678)
34. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695
35. Mikdashi J, Handwerger B, Langenberg P, et al. Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus. Stroke 2007;38:281-285 (Pubitemid 46184295)
36. Svenungsson E, Fei GZ, Jensen-Urstad K, et al. TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus 2003;12:454-461 (Pubitemid 36830119)
37. Linnemann B, Schindewolf M, Zgouras D, et al. Are patients with thrombophilia and previous venous thromboembolism at higher risk to arterial thrombosis? Thromb Res 2008;121:743-750 (Pubitemid 351492581)
38. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992;117:303-308
39. Pryshchep O, Ma-Krupa W, Younge BR, et al. Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation 2008;118:1276-1284
40. Atsumi T, Khamashta MA, Haworth RS, et al. Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1. Arthritis Rheum 1998;41:800-807 (Pubitemid 28225779)
41. Niessner A, Shin MS, Pryshchep O, et al. Synergistic proinflammatory effects of the antiviral cytokine interferon-alpha and Toll-like receptor 4 ligands in the atherosclerotic plaque. Circulation 2007;116:2043-2052 (Pubitemid 350023750)
42. Kariuki SN, Kirou KA, MacDermott EJ, et al. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 2009;182:34-38
43. Jönsen A, Bengtsson AA, Sturfelt G, et al. Analysis of HLA DR, HLA DQ, C4A, FcgammaRIIa, FcgammaRIIIa, MBL, and IL-1Ra allelic variants in Caucasian systemic lupus erythematosus patients suggests an effect of the combined FcgammaRIIa R/R and IL-1Ra 2/2 genotypes on disease susceptibility. Arthritis Res Ther 2004;6:R557-62.
44. Ståhl-Hallengren C, Jönsen A, Nived O, et al. Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 2000;27:685-691 (Pubitemid 30151347)
45. Martínez A, Varadé J, Márquez A, et al. Association of the STAT4 gene with increased susceptibility for some immune-mediated diseases. Arthritis Rheum 2008;58:2598-2602
46. Nordmark G, Kristjansdottir G, Theander E, et al. Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjögren's syndrome. Genes Immun 2009;10:68-76.
47. Zervou MI, Mamoulakis D, Panierakis C, et al. STAT4: a risk factor for type 1 diabetes? Hum Immunol 2008;69:647-650